ConductScience.org, home

Paper22472995

Safety and pharmacokinetics of escalating daily doses of the antituberculosis drug rifapentine in healthy volunteers.

Dooley KE and 9 others. Clin Pharmacol Ther, 2012. Cited by 72 papers, by iCite.

Cite this record

ConductScience Library. Safety and pharmacokinetics of escalating daily doses of the antituberculosis drug rifapentine in healthy volunteers. Papers, record 22472995. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/22472995

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Safety and pharmacokinetics of escalating daily doses of the antituberculosis drug rifapentine in healthy volunteers.
PubMed
Journal
Clin Pharmacol Ther
PubMed
Year
2012
PubMed
Publication types
Clinical Trial, Phase I, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.
PubMed
Citations, by iCite
72
iCite
Relative citation ratio, by iCite
2.58
iCite
Revised in PubMed
2021-10-21
PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Dooley KEK E
2Bliven-Sizemore EEE E
3Weiner MM
4Lu YY
5Nuermberger ELE L
6Hubbard WCW C
7Fuchs EJE J
8Melia MTM T
9Burman WJW J
10Dorman SES E

Source PubMed

Download CSV of authors

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antitubercular AgentsMajor topic
Drug-Related Side Effects and Adverse ReactionsMajor topic
RifampinMajor topic
Adult
Area Under Curve
Cytochrome P-450 CYP3A
Female
Humans
Male
Midazolam
Middle Aged

Source PubMed

Download CSV of topics

Grants6

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
1S10 RR 27733NCRR NIH HHSUnited StatesS10RR027733PubMed and NIHNIH RePORTER
P30 50410PHS HHSUnited StatesPubMedPubMed
UL1 RR025005NCRR NIH HHSUnited StatesUL1RR025005PubMed and NIHNIH RePORTER
K23 AI080842NIAID NIH HHSUnited StatesK23AI080842PubMed and NIHNIH RePORTER
S10 RR027733NCRR NIH HHSUnited StatesS10RR027733PubMed and NIHNIH RePORTER
K23AI080842NIAID NIH HHSUnited StatesK23AI080842PubMed and NIHNIH RePORTER

Download CSV of grants

Trials2

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's recordSource
NCT02563327Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of TuberculosisBackgroundClinicalTrials.gov
NCT06253715Shortened Regimen for Drug-susceptible TB in ChildrenBackgroundClinicalTrials.gov

Download CSV of trials

References31

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
120147896A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir.Clin Pharmacol Ther2010https://conductscience.org/library/papers/20147896PubMed
212241657Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial.Lancet2002https://conductscience.org/library/papers/12241657PubMed
33947503Induction of mixed function oxidase activity in man by rifapentine (MDL 473), a long-acting rifamycin derivative.Br J Clin Pharmacol1986https://conductscience.org/library/papers/3947503PubMed
416480505Roles of rifampicin in drug-drug interactions: underlying molecular mechanisms involving the nuclear pregnane X receptor.Ann Clin Microbiol Antimicrob2006https://conductscience.org/library/papers/16480505PubMed
516109981Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis.Am J Respir Crit Care Med2006https://conductscience.org/library/papers/16109981PubMed
6346286Clinical pharmacokinetics of rifampicin.Clin Pharmacokinet1978https://conductscience.org/library/papers/346286PubMed
718815591Dose-response of ritonavir on hepatic CYP3A activity and elvitegravir oral exposure.Clin Pharmacol Ther2009https://conductscience.org/library/papers/18815591PubMed
8684036Multicompartmental analysis of serum, urine and bile concentrations of rifampicin and desacetyl-rifampicin in subjects treated for one week.Pharmacol Res Commun1978https://conductscience.org/library/papers/684036PubMed
918037906Comparison of the induction profile for drug disposition proteins by typical nuclear receptor activators in human hepatic and intestinal cells.Br J Pharmacol2008https://conductscience.org/library/papers/18037906PubMed
109402947Primary human hepatocytes as a tool for the evaluation of structure-activity relationship in cytochrome P450 induction potential of xenobiotics: evaluation of rifampin, rifapentine and rifabutin.Chem Biol Interact1997https://conductscience.org/library/papers/9402947PubMed
1118723432Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis?Am J Respir Crit Care Med2008https://conductscience.org/library/papers/18723432PubMed
1216251279Population pharmacokinetics of rifapentine and its primary desacetyl metabolite in South African tuberculosis patients.Antimicrob Agents Chemother2005https://conductscience.org/library/papers/16251279PubMed
1316580903Comparison of midazolam and simvastatin as cytochrome P450 3A probes.Clin Pharmacol Ther2006https://conductscience.org/library/papers/16580903PubMed
144087830Pharmacokinetics of oral and intravenous rifampicin during chronic administration.Klin Wochenschr1985https://conductscience.org/library/papers/4087830PubMed
158549036Rifampin drastically reduces plasma concentrations and effects of oral midazolam.Clin Pharmacol Ther1996https://conductscience.org/library/papers/8549036PubMed
1616574936Potent twice-weekly rifapentine-containing regimens in murine tuberculosis.Am J Respir Crit Care Med2006https://conductscience.org/library/papers/16574936PubMed
1710730688Open-label, nonrandomized study of the effects of gatifloxacin on the pharmacokinetics of midazolam in healthy male volunteers.Pharmacotherapy2000https://conductscience.org/library/papers/10730688PubMed
1815844071Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis.Clin Infect Dis2005https://conductscience.org/library/papers/15844071PubMed
193628475Influence of the enzyme induction by rifampicin on its presystemic metabolism.Pharmacol Ther1987https://conductscience.org/library/papers/3628475PubMed
2018092886Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model.PLoS Med2007https://conductscience.org/library/papers/18092886PubMed

See all 31 referencesDownload CSV of references

Cited by51

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 72 citations.

PMIDTitleJournalYearIn PapersSource
42878247Pharmacokinetics of Rifapentine and Desacetyl Rifapentine in Maternal Plasma and Breast Milk & Infant Cord Blood and Plasma: A Model-Based Analysis of Mother-Infant Pairs for Tuberculosis Prevention.Clin Pharmacol Ther2026https://conductscience.org/library/papers/42878247PubMed
41609968A Validated LC-MS/MS Method for Unbound Rifapentine Quantitation Reveals Nonlinear Plasma Protein Binding and Comparable Free Fractions Between Adults and Children with Tuberculosis.Eur J Drug Metab Pharmacokinet2026https://conductscience.org/library/papers/41609968PubMed
41504451Dolutegravir concentrations in children receiving 3-month weekly isoniazid and rifapentine (3HP) for tuberculosis prevention.Microbiol Spectr2026https://conductscience.org/library/papers/41504451PubMed
41410856Unexpected Clinical Drug-Drug Interaction of Fexinidazole on Midazolam Pharmacokinetics: Insights into Underlying Mechanisms from Clinical Phase I Study Results and Supporting In Vivo/Vitro Evidence.Clin Drug Investig2026https://conductscience.org/library/papers/41410856PubMed
41047272Comparative efficacy and safety of high-dose rifamycin regimens for tuberculosis treatment: a Bayesian network meta-analysis.BMJ Open2025https://conductscience.org/library/papers/41047272PubMed
40990707New drugs for the management of tuberculosis.Curr Opin Infect Dis2025https://conductscience.org/library/papers/40990707PubMed
40560789Development and hepatotoxicity of rifamycin derivatives.Expert Opin Drug Metab Toxicol2025https://conductscience.org/library/papers/40560789PubMed
40080768Efficacy and Safety of Higher Doses of Levofloxacin for Multidrug-resistant Tuberculosis: A Randomized, Placebo-controlled Phase II Clinical Trial.Am J Respir Crit Care Med2025https://conductscience.org/library/papers/40080768PubMed
39477924Risk-stratified treatment for drug-susceptible pulmonary tuberculosis.Nat Commun2024https://conductscience.org/library/papers/39477924PubMed
39240337Therapeutic drug monitoring in tuberculosis.Eur J Clin Pharmacol2024https://conductscience.org/library/papers/39240337PubMed
37855280An Overview of Various Rifampicin Analogs against Mycobacterium tuberculosis and their Drug Interactions.Med Chem2024https://conductscience.org/library/papers/37855280PubMed
37321622Translational predictions of phase 2a first-in-patient efficacy studies for antituberculosis drugs.Eur Respir J2023https://conductscience.org/library/papers/37321622PubMed
37158831
Optimizing (O) rifapentine-based (RI) regimen and shortening (EN) the treatment of drug-susceptible tuberculosis (T) (ORIENT) using an adaptive seamless design: study protocol of a multicenter randomized controlled trial.
BMC Infect Dis2023https://conductscience.org/library/papers/37158831PubMed
36778546Effect of a modified regimen on drug-sensitive retreated pulmonary tuberculosis: A multicenter study in China.Front Public Health2023https://conductscience.org/library/papers/36778546PubMed
36588698Evaluation of drug-drug interaction between rilpivirine and rifapentine using PBPK modelling.Front Pharmacol2022https://conductscience.org/library/papers/36588698PubMed
36516792New and Repurposed Drugs for the Treatment of Active Tuberculosis: An Update for Clinicians.Respiration2023https://conductscience.org/library/papers/36516792PubMed
35722783Alternatives to rifampicin: A review and perspectives on the choice of strong CYP3A inducers for clinical drug-drug interaction studies.Clin Transl Sci2022https://conductscience.org/library/papers/35722783PubMed
35462285Validation and application of a quantitative liquid chromatography tandem mass spectrometry assay for the analysis of rifapentine and 25-O-desacetyl rifapentine in human milk.J Pharm Biomed Anal2022https://conductscience.org/library/papers/35462285PubMed
35120633Use of integrase inhibitors in HIV-associated tuberculosis in high-burden settings: implementation challenges and research gaps.Lancet HIV2022https://conductscience.org/library/papers/35120633PubMed
34623770Development of physiologically-based pharmacokinetic models for standard of care and newer tuberculosis drugs.CPT Pharmacometrics Syst Pharmacol2021https://conductscience.org/library/papers/34623770PubMed

See all 51 cited byDownload CSV of cited by

Genes5

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ABCB15243PubTator's text mininghttps://conductscience.org/library/genes/5243NCBI Gene
CYP3A41576PubTator's text mininghttps://conductscience.org/library/genes/1576NCBI Gene
CYP4F34051PubTator's text mininghttps://conductscience.org/library/genes/4051NCBI Gene
NR1I28856PubTator's text mininghttps://conductscience.org/library/genes/8856NCBI Gene
SLCO1B110599PubTator's text mininghttps://conductscience.org/library/genes/10599NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/22472995

GET https://conductscience.org/api/papers/v1/22472995/references?page=2